Carey L A, Perou C M, Livasy C A, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA, 2006, 295(21): 2492-2502. [2]Gucalp A, Traina T A. Triple-negative breast cancer: adjuvant therapeutic options[J]. Chemother Res Pract, 2011, 2011: 696208. [3]Dent R, Hanna W M, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer[J]. Breast Cancer Res Treat, 2009, 115(2): 423-428. [4]Harris L N, Broadwater G, Lin N U, et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342[J]. Breast Cancer Res, 2006, 8(6): R66. [5]Luo H, Yang G, Yu T, et al. GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts[J]. Endocr Relat Cancer, 2014, 21(2): 355-369. [6]Mo Z, Liu M, Yang F, et al. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer[J]. Breast Cancer Res, 2013, 15(6): R114. [7]Fujiwara S, Terai Y, Kawaguchi H, et al. GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer[J]. J Ovarian Res, 2012, 5(1): 35. [8]Vivacqua A, Bonofiglio D, Recchia A G, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells[J]. Mol Endocrinol, 2006, 20(3): 631-646. [9]Bologa C G, Revankar C M, Young S M, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30[J]. Nat Chem Biol, 2006, 2(4): 207-212. [10]Dennis M K, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist[J]. Nat Chem Biol, 2009, 5(6): 421-427. [11]Steiman J, Peralta E A, Louis S, et al. Biology of the estrogen receptor, GPR30, in triple negative breast cancer[J]. Am J Surg, 2013, 206(5): 698-703. [12]Dent R, Trudeau M, Pritchard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434. [13]Aghili M, Lashkari M, Farrokhpey A H, et al. Triple-negative breast cancer survival in Iranian patients[J]. Acta Med Iran, 2013, 51(8): 560-566. [14]Tu G, Hu D, Yang G, et al. The correlation between GPR30 and clinicopathologic variables in breast carcinomas[J]. Technol Cancer Res Treat, 2009, 8(3): 231-234. [15]Girgert R, Emons G, Grundker C. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy[J]. Breast Cancer Res Treat, 2012, 134(1): ？199-205？. [16]Saini K S, Loi S, de-Azambuja E, et al. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer[J]. Cancer Treat Rev, 2013, 39(8): 935-946. [17]李维东, 罗浩军, 李振华, 等. 雌激素激活GPER-EGFR-ERK通路促进人乳腺癌SKBR-3细胞系增殖[J]. 第三军医大学学报, 2012, 34(22): 2283-2287. [18]Pandey D P, Lappano R, Albanito L, et al. Estrogenic GPR30 signaling induces proliferation and migration of breast cancer cells through CTGF[J]. EMBO J, 2009, 28(5): 523-532. [19]Ohshiro K, Schwartz A M, Levine P H, et al. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells ？via？ non-genomic signaling[J]. PLoS One, 2012, 7(1): e30725.
